cyclic peptideTherapeutic Peptides
Motixafortide (Aphexda)
First peptide CXCR4 antagonist approved for stem cell mobilization in multiple myeloma patients. Blocks the CXCR4/CXCL12 axis to release hematopoietic stem cells from bone marrow into blood for transplant collection.
stem-cell-mobilizationCXCR4-antagonistmultiple-myelomaFDA-approved
Lab Tested
No
Harmful Ingredients
0
Contaminants
None
Tested Purity
--
Batch Consistency
No batch data
Mass Spec Profile
ESI-MS (computed)
Batch Info
Latest Batch—
Total Tests0
Unique Vendors0
Vendor Comparison
No vendor data yet
Analysis Summary
Purity Standard
No purity dataLab Reports
0 reports on file
Summary
First peptide CXCR4 antagonist approved for stem cell mobilization in multiple myeloma patients. Blocks the CXCR4/CXCL12 axis to release hematopoietic stem cells from bone marrow into blood for transp…